Dyadic International (NASDAQ:DYAI – Get Free Report) and Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Earnings & Valuation
This table compares Dyadic International and Spyre Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dyadic International | $3.09 million | 5.91 | -$7.36 million | ($0.23) | -1.98 |
| Spyre Therapeutics | $890,000.00 | 9,208.01 | -$155.20 million | ($1.95) | -47.79 |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Dyadic International and Spyre Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dyadic International | 1 | 0 | 1 | 0 | 2.00 |
| Spyre Therapeutics | 1 | 1 | 13 | 1 | 2.88 |
Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 558.18%. Spyre Therapeutics has a consensus target price of $109.71, suggesting a potential upside of 17.73%. Given Dyadic International’s higher probable upside, equities analysts clearly believe Dyadic International is more favorable than Spyre Therapeutics.
Risk & Volatility
Dyadic International has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500.
Insider & Institutional Ownership
27.9% of Dyadic International shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Dyadic International and Spyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dyadic International | -201.43% | -2,920.31% | -84.77% |
| Spyre Therapeutics | N/A | -30.74% | -22.23% |
Summary
Spyre Therapeutics beats Dyadic International on 9 of the 15 factors compared between the two stocks.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
About Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
